



Iran (Islamic Republic of)

Eastern Mediterranean Region



I. Epidemiological profile

Population (UN)	2015	%
Number of active foci	141	
Number of people living within active foci	692,000	1
Malaria-free (0 cases)	78,418,000	99
Total	79,110,000	

Parasites and vectors			
Plasmodium species:	<i>P. falciparum</i> (13%), <i>P. vivax</i> (86%)		
Major anopheles species:	<i>An. stephensi</i> , <i>An. culicifacies</i> , <i>An. fluviatilis</i> , <i>An. superpictus</i>		
Reported confirmed cases (health facility):	1,378	Estimated cases:	180 [170 ; 200]
Confirmed cases at community level:	-		
Reported deaths:	1	Estimated deaths:	<10

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/ LLINs distributed free of charge	Yes	2005
	ITNs/ LLINs distributed to all age groups	Yes	2005
IRS	IRS is recommended	Yes	1949
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	1949
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	Yes	1949
Treatment	ACT is free of charge for all ages in public sector	Yes	2005
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	1949
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	1949
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	1949
	System for monitoring adverse reactions to antimalarials exists	Yes	1949
Surveillance	ACD for case investigation (reactive)	No	1949
	ACD of febrile cases at community level (pro-active)	Yes	1949
	Mass screening is undertaken	No	-
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-
	Foci and case investigation undertaken	Yes	2010
	Case reporting from private sector is mandatory	Yes	1949


Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	AS+SP; AS+SP+PQ	-
First-line treatment of <i>P. falciparum</i>	AS+SP; AS+SP+PQ	2010
Treatment failure of <i>P. falciparum</i>	AL; AL+PQ	2010
Treatment of severe malaria	AS; QN	-
Treatment of <i>P. vivax</i>	CQ+PQ(14d & 8w)	-
Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.75 mg/Kg (8 weeks)
Type pf RDT used	P.f + all species (Combo)	

Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
AS+SP	2005-2012	0	0	1	28 days	15	<i>P. falciparum</i>
CQ+PQ	2008-2011	0	0	0	28 days	4	<i>P. vivax</i>


Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)					
Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested
2010-2012	Yes	Yes	Yes	Yes	<i>An. stephensi</i> , <i>An. culicifacies</i> , other

III. Financing

Sources of financing




Government expenditure by intervention in 2015 2015




IV. Coverage

Coverage of ITN and IRS




Cases tested




V. Impact


Cases treated



Test positivity



Confirmed malaria cases per 1000 and ABER



Number of malaria cases

